BeCytes Biotechnologies

BeCytes Biotechnologies, based in Spain, specializes in providing fresh, cryopreserved, and plateable hepatic cells essential for biomedical research, including drug development and toxicity testing. Founded in 2015 in Barcelona, Spain, BeCytes Biotechnologies focuses on the supply of hepatic cells for research purposes. The company has engaged in one notable deal to date, with the most recent transaction recorded on December 11, 2025. BeCytes was acquired by BioIVT, LLC, a portfolio company of Linden Capital Partners and Arsenal Capital Partners; financial terms of this transaction were not disclosed.

BeCytes Biotechnologies specializes in a comprehensive range of hepatic cells, including Primary Human Hepatocytes, Plateable Primary Human Hepatocytes (Cryo), and Human Suspension Hepatocytes sourced from both human and animal origins. These products are critical in biomedical research settings, particularly for drug development and toxicity testing, and the company also facilitates human tissue sourcing for research purposes. Its clientele comprises academic institutions, pharmaceutical companies, and biotechnology firms across Europe and North America. Operating on a B2B transaction model, BeCytes Biotechnologies supplies specialized hepatic cells and tissue sourcing services directly to clients such as research institutions and pharmaceutical companies.

Revenue is generated through direct sales of these products, with bulk orders tailored to meet the specific needs of clients. The revenue structure reflects both the scale of orders and the long-term partnerships fostered with clients engaged in ongoing research projects and preclinical studies. Following its acquisition by BioIVT, LLC in December 2025, BeCytes Biotechnologies aims to leverage the acquisition to enhance its market reach and product development capabilities. The integration with BioIVT is expected to facilitate the expansion into new markets and geographic regions, although specific areas for growth have not been disclosed.

The company plans to utilize the resources from this acquisition to bolster its product offerings and support ongoing research efforts.